FINDING THE CHALLENGES OF ERADICATING HELICOBACTER PYLORI AMIDST RISING ANTIBIOTIC RESISTANCE: FUTURE STRATEGIES TO OVERCOME THE HURDLES

Authors

  • Saima Bahar
  • Nimra Tul Ain Khan
  • Sayyeda Aisha Bahar
  • Raees Ahmed
  • Kinjal Shah
  • Kaksha Parrikh

DOI:

https://doi.org/10.53555/c3w4bb85

Keywords:

H. pylori, antibiotic resistance, eradication, treatment failure

Abstract

ABSTRACT

Background: H. pylori is known to be involved in the etiology of chronic gastritis, peptic ulcer disease and gastric cancer. It has been argued that due to the enhanced antibiotic resistance it has become very difficult to eliminate H. pylori completely through the standard regimes of treatment and it has resulted in higher treatment failure rates.

Objectives: To compare the effect of antibiotic resistance on the rate of H. pylori eradication and other approaches to optimizing the therapy.

Study Design: A Cross Sectional Study

Duration and place of study: Medicine Department, Ayub Teaching Hospital- Abbottabad, from Jan 2022 to Jan 2023.

Methods: One hundred and fifty patients with H. pylori infection confirmed were recruited in the study. All patients received the standard probability of triple therapy including clarithromycin, amoxicillin, and a proton pump inhibitor for 14 days. Antibiotic sensitivities and resistance were established by culture and sensitivity. Parameters measured in the treatment included overall success rate, mean age, standard deviation and p-values.

Results:  As to demographics, the average patient age was 45. 6 years (SD = 12. 3). Among 150 patients; 55% were resistant to clarithromycin while 30% to metronidazole. The pooled eradication rate was 65%; however, it was much lower among patients with antibiotic-resistant strains (p = 0. 002). Upon comparing the results on antibiotic resistance with the findings on treatment failure the values were closely related with the p value coming to < 0. 05.

Conclusion: The general efficacy of standard H. pylori treatment regimens has been compromised by the gradual increase in antibiotic resistance. Other approaches such as individualised antibiotic management, as well as the application of new classes of drugs need to be employed in order to address these issues and to enhance levels of clearance.

Author Biographies

  • Saima Bahar

    MBBS, FCPS Gastroenterology, Medicine Department, DHQ Hospital, Nowshera

  • Nimra Tul Ain Khan

    Internal Medicine Department, Ayub Teaching Hospital, Abbottabad, Pakistan

  • Sayyeda Aisha Bahar

    MBBS, Ayub Medical College, Resident Physician, Ayub Teaching Hospital, Abbottabad

  • Raees Ahmed

    MBBS Student, Internal Medicine, Ayub Teaching Hospital, Abbottabad.

  • Kinjal Shah

    MBBS, Pramukhswami Medical College, Anand, India Department: Internal Medicine

  • Kaksha Parrikh

    MBBS, Government Medical College, Bhavnagar, Gujarat, India Department: Internal Medicine

References

1. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. The Lancet. 1984;323(8390):1311-1315.

2. Suerbaum S, Michetti P. Helicobacter pylori infection. New England Journal of Medicine. 2002;347(15):1175-1186.

3. Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report. Gut. 2017;66(1):6-30.

4. Savoldi A, Carrara E, Graham DY, et al. Clarithromycin-resistant Helicobacter pylori: A systematic review and meta-analysis. Gut. 2018;67(1):17-24.

5. Thung I, Aramin H, Vavinskaya V, et al. Review article: The global emergence of Helicobacter pylori antibiotic resistance. Alimentary Pharmacology & Therapeutics. 2016;43(4):514-533.

6. Gerrits MM, van Vliet AH, Kuipers EJ, Kusters JG. Biofilm formation and its role in Helicobacter pylori pathogenesis. Applied and Environmental Microbiology. 2006;72(3):2247-2250.

7. Venerito M, Vasapolli R, Rokkas T, Malfertheiner P. Helicobacter pylori and gastric cancer: A concise review on current knowledge. Annals of Gastroenterology. 2019;32(4):374-381.

8. Gisbert JP, Calvet X. Review article: Rifabutin in the treatment of refractory Helicobacter pylori infection. Alimentary Pharmacology & Therapeutics. 2012;35(2):209-221.

9. Liou JM, Chen CC, Chen MJ, et al. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: A multicentre, open-label, randomized trial. The Lancet. 2013;381(9862):205-213.

10. Graham DY, Fischbach L. Empiric therapies for Helicobacter pylori infections. The Journal of Clinical Gastroenterology. 2014;48(5):322-327.

11. Murakami K, Sakurai Y, Shiino M, et al. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: A phase III, randomized, double-blind study. Gut. 2016;65(9):1439-1446.

12. Szajewska H, Horvath A, Piwowarczyk A. Meta-analysis: The effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Alimentary Pharmacology & Therapeutics. 2010;32(9):1069-1079.

13. Savoldi A, Carrara E, Graham DY, et al. Clarithromycin-resistant Helicobacter pylori: A systematic review and meta-analysis. Gut. 2018;67(1):17-24.

14. Thung I, Aramin H, Vavinskaya V, et al. Review article: The global emergence of Helicobacter pylori antibiotic resistance. Alimentary Pharmacology & Therapeutics. 2016;43(4):514-533.

15. Gisbert JP, Calvet X. Review article: Rifabutin in the treatment of refractory Helicobacter pylori infection. Alimentary Pharmacology & Therapeutics. 2012;35(2):209-221.

16. Graham DY, Fischbach L. Empiric therapies for Helicobacter pylori infections. The Journal of Clinical Gastroenterology. 2014;48(5):322-327.

17. Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report. Gut. 2017;66(1):6-30.

18. Thung I, Aramin H, Vavinskaya V, et al. Review article: The global emergence of Helicobacter pylori antibiotic resistance. Alimentary Pharmacology & Therapeutics. 2016;43(4):514-533.

19. Liou JM, Chen CC, Chen MJ, et al. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: A multicentre, open-label, randomized trial. The Lancet. 2013;381(9862):205-213.

20. Murakami K, Sakurai Y, Shiino M, et al. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: A phase III, randomized, double-blind study. Gut. 2016;65(9):1439-1446.

21. Szajewska H, Horvath A, Piwowarczyk A. Meta-analysis: The effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Alimentary Pharmacology & Therapeutics. 2010;32(9):1069-1079.

22. Venerito M, Vasapolli R, Rokkas T, Malfertheiner P. Helicobacter pylori and gastric cancer: A concise review on current knowledge. Annals of Gastroenterology. 2019;32(4):374-381.

Downloads

Published

2024-08-24

How to Cite

Saima Bahar, Nimra Tul Ain Khan, Sayyeda Aisha Bahar, Raees Ahmed, Kinjal Shah, & Kaksha Parrikh. (2024). FINDING THE CHALLENGES OF ERADICATING HELICOBACTER PYLORI AMIDST RISING ANTIBIOTIC RESISTANCE: FUTURE STRATEGIES TO OVERCOME THE HURDLES. Journal of Population Therapeutics and Clinical Pharmacology, 31(8), 1463-1469. https://doi.org/10.53555/c3w4bb85
More Citation Formats

Issue

Section

Articles

How to Cite

Saima Bahar, Nimra Tul Ain Khan, Sayyeda Aisha Bahar, Raees Ahmed, Kinjal Shah, & Kaksha Parrikh. (2024). FINDING THE CHALLENGES OF ERADICATING HELICOBACTER PYLORI AMIDST RISING ANTIBIOTIC RESISTANCE: FUTURE STRATEGIES TO OVERCOME THE HURDLES. Journal of Population Therapeutics and Clinical Pharmacology, 31(8), 1463-1469. https://doi.org/10.53555/c3w4bb85

Most read articles by the same author(s)